Pain Management Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Pain Management. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Pain Management Indian Medical PG Question 1: Which of the following is the platinum-based chemotherapeutic agent used as first-line treatment for ovarian carcinoma?
- A. Cyclophosphamide
- B. Methotrexate
- C. Cisplatin (Correct Answer)
- D. Dacarbazine
Pain Management Explanation: ***Cisplatin***
- **Cisplatin** is a platinum-based chemotherapy drug that forms **DNA cross-links**, inhibiting DNA synthesis and leading to the death of rapidly dividing cells, making it highly effective against **ovarian carcinoma**.
- It is a cornerstone of chemotherapy regimens for ovarian cancer, often used in combination with other agents such as paclitaxel.
*Methotrexate*
- **Methotrexate** is an **antimetabolite** that inhibits dihydrofolate reductase, thereby interfering with DNA synthesis.
- While it is used in various cancers like leukemia, lymphoma, and some solid tumors (e.g., breast cancer, gestational trophoblastic disease), it is **not a primary recommended drug for ovarian carcinoma**.
*Cyclophosphamide*
- **Cyclophosphamide** is an **alkylating agent** that causes DNA damage, leading to cell death.
- It is used in many cancers, including lymphoma, breast cancer, and some leukemias, but it is **not a first-line or primary agent for ovarian carcinoma** in contemporary treatment guidelines.
*Dacarbazine*
- **Dacarbazine** is an **alkylating agent** primarily used in the treatment of **malignant melanoma** and Hodgkin lymphoma.
- It is **not indicated for the treatment of ovarian carcinoma**.
Pain Management Indian Medical PG Question 2: Which of the following is not seen in chronic regional pain syndrome?
- A. Anhidrosis (Correct Answer)
- B. Severe Pain
- C. Swelling
- D. Osteoporosis
Pain Management Explanation: ***Anhidrosis***
- **Anhidrosis**, or the **absence of sweating**, is generally *not* a characteristic feature of chronic regional pain syndrome (CRPS); rather, **hyperhidrosis** (excessive sweating) is often observed in the affected limb.
- CRPS typically involves sympathetic nervous system dysfunction, which can lead to changes in sudomotor activity, usually resulting in increased rather than decreased sweating.
*Severe Pain*
- **Severe, unremitting pain** is the cardinal symptom of CRPS and is disproportionate to the initial injury, if any.
- The pain is often described as burning, throbbing, or aching and can spread beyond the site of injury.
*Swelling*
- **Edema** or **swelling** of the affected limb is a common finding in CRPS, especially in the early stages.
- This swelling can be accompanied by changes in skin temperature and color due to vasomotor dysfunction.
*Osteoporosis*
- **Osteoporosis** or **bone demineralization** is a common complication in CRPS, particularly in later stages.
- It results from increased osteoclastic activity and reduced bone formation, which can be seen on imaging as patchy or diffuse bone loss.
Pain Management Indian Medical PG Question 3: Which of the following types of nerve fibers are primarily responsible for transmitting slow, dull, and chronic pain sensations?
- A. A-alpha fibers
- B. A-beta fibers
- C. A-delta fibers
- D. C fibers (Correct Answer)
Pain Management Explanation: ***C fibers***
- These are **unmyelinated**, small-diameter nerve fibers that conduct impulses slowly (0.5-2 m/s).
- They are primarily responsible for transmitting **slow, dull, burning, or aching pain** (second pain or chronic pain), as well as temperature sensations and itch.
- Their slow conduction velocity results in the delayed, poorly localized pain sensation that persists after initial injury.
*A-alpha fibers*
- These are the **largest and fastest-conducting** myelinated nerve fibers (70-120 m/s).
- They are primarily involved in transmitting **proprioception** (sense of body position) and **motor information** to skeletal muscles.
- They do **not transmit pain** signals.
*A-beta fibers*
- These are **large, myelinated** fibers with a fast conduction velocity (30-70 m/s).
- They primarily transmit **touch and pressure sensations**, and can modulate pain perception through the gate control theory.
- They are **not nociceptors** and do not directly transmit pain.
*A-delta fibers*
- These are **small, myelinated** nerve fibers that conduct impulses at 12-30 m/s.
- They transmit **fast, sharp, well-localized pain** (first pain or acute pain) and cold sensations.
- While they do transmit pain, they are responsible for the **initial sharp pain**, not the slow, dull, chronic pain that defines C fiber function.
Pain Management Indian Medical PG Question 4: Which type of pain is characterized by unknown etiology?
- A. Nociceptive pain
- B. Neuropathic pain
- C. Idiopathic pain (Correct Answer)
- D. Inflammatory pain
Pain Management Explanation: ***Idiopathic pain***
- This term refers to pain where the **underlying cause** or pathology cannot be identified, despite thorough investigation.
- It signifies that the **etiology is unknown**, fitting the description in the question directly.
*Nociceptive pain*
- This type of pain arises from the activation of **nociceptors** due to actual or threatened tissue damage.
- Its etiology is typically clear, involving an injury, inflammation, or mechanical stress.
*Neuropathic pain*
- This pain results from damage or disease affecting the **somatosensory nervous system**.
- The etiology is known to be nerve damage or dysfunction, not an unknown origin.
*Inflammatory pain*
- This pain is driven by the inflammatory process, involving the release of **pro-inflammatory mediators** at the site of tissue injury or infection.
- The cause is directly linked to inflammation, making its etiology known.
Pain Management Indian Medical PG Question 5: Which of the following pain medications requires the MOST caution in a patient with a history of opioid addiction?
- A. Morphine (Correct Answer)
- B. Oxycodone
- C. Methadone
- D. Buprenorphine
Pain Management Explanation: ***Morphine***
- Morphine is a **full mu-opioid agonist** with the highest potential for **abuse, dependence, and relapse** in patients with a history of opioid addiction due to its strong **euphoric effects**.
- It carries the greatest risk of triggering **addictive behaviors** and relapse in recovering patients, making it require the MOST caution in this population.
- Use should be avoided if possible, or limited to short-term use under strict supervision with alternative analgesics preferred.
*Oxycodone*
- Oxycodone is another **potent full opioid agonist** with very high abuse potential, nearly equivalent to morphine.
- While requiring extreme caution, morphine remains the prototypical high-risk opioid in addiction-prone patients.
*Methadone*
- Methadone is a **long-acting full opioid agonist** used in opioid maintenance therapy with significant abuse potential.
- However, when used appropriately in supervised programs, it has a role in addiction treatment, though acute pain prescribing requires caution due to its **long half-life and QTc prolongation risk**.
*Buprenorphine*
- Buprenorphine is a **partial mu-opioid agonist** with a **ceiling effect** that limits respiratory depression and euphoria.
- It is the **standard medication for opioid use disorder treatment** and has LOWER abuse potential than full agonists.
- While it requires careful timing to avoid precipitated withdrawal in opioid-dependent patients, it is actually SAFER than full agonists in patients with addiction history due to reduced relapse risk.
More Pain Management Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
